|
Bonnie Anderson
CEO, Veracyte
Bonnie Anderson is the cofounder of Veracyte and has served as Chief Executive Officer since 2008. She has more than 25 years of experience leading early-stage businesses to mature enterprises in diagnostics and life sciences. Prior to Veracyte, Ms. Anderson provided strategic consulting services to venture capital firms and early-stage businesses following 18 years at Beckman Coulter, including Vice President of the intra-preneurial Immunomics Operations. She currently serves as a member of the Board of Trustees of Keck Graduate Institute of Life Sciences and on the advisory board for Bay Bio. She has also served on the boards of Thymed, GmbH and Women in Biotechnology.
[ Back to top ]
Brian Atwood
Managing Director, Versant Ventures
Brian Atwood specializes in biotechnology investing at Versant. Brian is a cofounder of Versant Ventures and before this spent four years at Brentwood Venture Capital where, as a general partner, he led investments in biotechnology, pharmaceuticals, and bioinformatics. He also has more than 15 years of operating experience in the biotechnology industry, with emphasis on therapeutic products, devices, diagnostics, and research instrumentation. Prior to launching his career in venture capital, Brian was founder, president, and CEO of Glycomed, a publicly traded biotechnology company. At Glycomed, Brian concentrated on business development and strategic alliances, closing deals with Eli Lilly & Company, Millipore, Genentech and Sankyo, before leading the sale of Glycomed to Ligand Pharmaceuticals. Prior to this, he co-founded and served as director of Perkin Elmer/Cetus Instruments, a joint venture for robotics automation and genomics research instruments and products later acquired by Perkin Elmer. Under Brian's management, the venture developed and launched the GeneAmp® Polymerase Chain Reaction (PCR) system, the fundamental DNA amplification innovation responsible for fueling the explosive growth of genomics research. Brian served on the Board of Directors at Pharmion Corporation (sold to Celgene in 2008). Brian currently serves as a Board member at the private companies FivePrime Therapeutics, Inc., Veracyte, Inc., OpGen, Inc., PhaseRx, Inc., Clovis Pharmaceuticals, Immune Design Corp., and Mirina Corporation, as well as the public companies, Cadence Pharmaceuticals (CADX), Helicos Biosciences (HLCS), and Trius Therapeutics, Inc. Brian received a Bachelor's degree in Biological Sciences from the University of California, Irvine; a Master's degree from the University of California, Davis, and an MBA from Harvard Business School.
[ Back to top ]
Bob Behl
CEO, Percutaneous Systems Inc.
Robert Behl is a serial entrepreneur with a start-up focused career spanning nearly three decades. After professional and line management positions in R&D, Marketing, and Business Development with three major medical device companies, Behl founded and served as GM of Clinical Technology, a division of lab and tech conglomerate, Sybron Corp. Returning to his California roots after the sale of Clin Tech to MDT and Maxxim, he served as CEO and concluded a turn-around and refocus of Menlo Care, a Raychem Corp. spinout, later acquired by Johnson & Johnson. Beginning personal startups in 1989, Behl founded InnerDyne (later sold to Tyco/Covidien), RadioTherapeutics (later sold to Boston Scientific) and Percutaneous Systems or PercSys, in all of these serving as the initial CEO and CFO. He currently serves as Chairman of the Board and CFO of PercSys, a company bringing into the market new and unique treatments for the 1.7MM patients annually suffering from kidney stones. During his career, Behl has raised more than $80MM in venture capital and venture debt for his companies. Mr. Behl is heavily involved with general entrepreneurial and life science mentoring activities, and is one of the charter members of Life Science Angels. He and his wife are actively involved with the research and organizational activities of the Leukemia & Lymphoma Society. Mr. Behl holds a BS in Mechanical Engineering from CSUN, an MS in Biomedical Engineering from USC, and was awarded an MBA (Economics/Finance) from the Wm. Simon GSM at the University of Rochester. Mr. Behl holds 30 U.S. medical device patents.
[ Back to top ]
Leslie Bottorff
Partner, ONSET Ventures
Leslie Bottorff joined ONSET Ventures in 1998 after 19 years in the medical industry. At ONSET Ventures, Leslie specializes in medical technology investment opportunities. She has worked closely with several portfolio company entrepreneurs at the seed stage to formulate and validate their companies’ business plans, including Embolic Protection, where she was interim VP of Marketing and Business Development at inception. Leslie has served in board or advisory roles for several portfolio companies including Spinal Concepts, Novasys Medical, VisionCare Ophthalmic Technologies, Neuronetics, Sadra Medical, Aragon Surgical, Flexuspine and Relievant. Prior to joining ONSET, Leslie was VP of Sales and Marketing of Medtronic’s CardioRhythm division. She has also served in various marketing and sales management positions at both venture backed start-up companies and in large companies, including Nellcor, Ventritex, Menlo Care and General Electric’s Medical Systems division. Leslie has a B.S. in Biomedical Engineering from Purdue University and an MBA from Harvard Business School. She serves on advisory boards or as program faculty at several universities, including Stanford University and Purdue University, and is a member of the Board of Directors of the Al Mann Institute at Purdue University.
[ Back to top ]
Todd C. Carpenter
Partner, Wilson Sonsini Goodrich & Rosati
Todd Carpenter is a partner at Wilson Sonsini Goodrich & Rosati in Palo Alto. He specializes in corporate finance and corporate law and governance. Todd also has considerable expertise in the areas of mergers and acquisitions and venture capital. Tom received his J.D. from George Washington University Law School, graduating cum laude, and his undergraduate degree from Denison University. He is admitted to practice in California.
[ Back to top ]
David Cassak
Vice President, Content and Managing Director,
Medical Devices, Elsevier Business Intelligence
David Cassak is a vice president of content and managing director of medical devices for Elsevier Business Intelligence, a Reed Elsevier Company. He has been involved with the healthcare industry for more than 30 years and writes extensively on the medical device industry for Windhover’s IN VIVO and Start-Up. He is also a frequent speaker before various companies and industry trade groups. Prior to joining Elsevier, David worked for nearly 20 years at Windhover Information, Inc., a company he founded with his partner, Roger Longman, which spun out the publications business of The Wilkerson Group, a leading management consulting firm at the time. Long known for publishing IN VIVO, widely recognized as the premier provider of business intelligence in the healthcare industry, Windhover launched a number of other publications, including Start-Up: Emerging Medical Ventures,™ and The RPM Report: Regulation • Policy • Market Access.™ In 2004, Windhover acquired Medtech Insight, Inc., and now publishes the Medtech Insight: Medical Technology Market Intelligence™ newsletter. In addition, Windhover also created the Strategic Intelligence Systems (SIS), a Web-based suite of databases, featuring the most comprehensive and detailed source of industry alliances, acquisitions, and financings. In 2008, Windhover was acquired by Elsevier, which formed Elsevier Business Intelligence, combining the products of Windhover and FDC Reports, publishers of The Gray Sheet and The Pink Sheet, among other leading industry newsletters.
[ Back to top ]
Andrew Cleeland
CEO, Ardian
Andrew Cleeland is an executive with more than 20 years in the medical device industry. He is currently Vice President of Medtronic Ardian. Andrew was, prior to its recent acquisition by Medtronic, president, CEO, and director of Ardian, Inc. - a pioneering, private medical device company developing a novel catheter-based treatment for hypertension, heart failure and chronic kidney disease. Ardian’s recent exit was one of the highest priced venture capital-backed medical device transactions ever. Andrew's experience includes both private and public sector roles. He started with the Australian Therapeutic Goods Administration, progressed to large medtech companies in Telectronics Pacing Systems and Baxter Healthcare, then onto two Bay Area start-ups in Radiant Medical and Ardian, Inc. He holds a Bachelor of Applied Science (Biophysics) from the Swinburne Institute of Technology.
[ Back to top ]
Chad Cornell
VP of Corporate Development, Medtronic
In January of 2009 Chad Cornell was appointed Vice President of Medtronic Business Development. In this role Chad is responsible for oversight and coordination of Medtronic's Mergers and Acquisitions, Licensing, and Minority Investment activity. Chad joined the Medtronic Business Development group in April of 2005 as a Director and was subsequently promoted to Sr. Director in February of 2008. In this role Chad was responsible for supporting Medtronic business units in effecting strategic transactions for Medtronic. Chad worked in partnership with executive and business unit management in evaluating and executing mergers and acquisitions, strategic alliances, joint ventures, minority investments, technology licenses, divestitures and other strategic transactions. Chad also assisted in Medtronic's strategic planning process. Prior to joining Corporate Development, Chad was Legal Counsel – M&A, responsible for advising Corporate Development on strategic transactions across Medtronic. Chad began his career with Medtronic in 2003. Prior to joining Medtronic, Chad spent approximately five years as an associate attorney at Sidley & Austin in Chicago, Illinois working on mergers and acquisitions and securities offerings. Chad received his undergraduate degree in Accounting from Marquette University and a Juris Doctorate from the University of Pennsylvania. Chad has also successfully completed Certified Public Accountant and Chartered Financial Analyst examinations.
[ Back to top ]
Leo Cunningham
Partner, Wilson Sonsini Goodrich & Rosati
Leo Cunningham is a partner in Wilson Sonsini Goodrich & Rosati's litigation practice. He focuses on complex business-related disputes, including the defense of white collar crimes, civil securities cases, class actions, representative actions, and government investigations. Leo served as a member of the Judicial Conference of the United States' Advisory Committee on the Federal Rules of Criminal Procedure, having been appointed to a three-year term by Chief Justice Roberts in 2006. In addition, Leo was appointed by the judges of the Northern District of California to be a lawyer representative to the Ninth Circuit Court of Appeals' judicial conference from 2003 to 2006. He was appointed co-chairperson of the Northern District of California's lawyer representatives for 2006. Leo lectures regularly on a variety of topics, including federal sentencing, issues in securities litigation, and the Foreign Corrupt Practices Act, and he currently serves as a member of the firm's Policy Committee. Leo received his J.D. from Harvard Law School and his undergraduate degree from Stanford University. He is admitted to practice in California.
[ Back to top ]
Mark E. Deem
Partner, The Foundry, LLC
Mr. Deem joined The Foundry at its inception in 1998. In addition to spearheading the research and invention process on new clinical opportunities, Mr. Deem leads the early stage effort in The Foundry's new companies until the company's CEO and Senior Staff is hired.
Prior to joining The Foundry, Mr. Deem served in a founding role as consulting Director of Research and Development for Ventrica, Inc. Previously, Mr. Deem was a senior member of the Research & Development team at Medtronic Micro Interventional Systems. Mr. Deem joined MIS as one of the initial members of the company's engineering team and remained there through the acquisition by Medtronic.
Previously, Mr. Deem held engineering positions with Devices for Vascular Engineering, Cordis Corporation and the USCI Division of C.R. Bard.
Mr. Deem has spent over twenty years in the design, testing and manufacture of medical devices. He is a co-inventor on over 150 issued and pending U.S. patents. Mr. Deem earned his B.S. degree in biomedical engineering from Boston University.
Mr. Deem serves as a Director for Cabochon Aesthetics and Innovative Pulmonary Solutions, and as Chairman of Miramar Labs.
[ Back to top ]
Michael Devine
EVP, Sales & Marketing, Access Closure
Prior to joining AccessClosure, Michael Devine was the President, North America for TSC, Inc. a global manufacturer of rapid infusion systems and products to prevent hypothermia, where he was responsible for building the commercial strategy for North America. Prior to TSC, Inc., he served as the Vice President of Sales and Marketing for Confluent Surgical, an Incept company that was acquired by Tyco Healthcare. Prior to Confluent Surgical, Michael spent 16 years with Smiths Medical where he held a variety of sales, marketing and general management roles including Vice President & General Manager of Bivona Medical Technologies and President of Level 1, Inc. Subsequently, Smiths Medical consolidated their portfolio of companies and he was named the Vice President of Sales and Corporate Contracts for the combined entity. Michael received a B.S. in Business Administration from California State University, Northridge and an MBA from Northeastern University.
[ Back to top ]
Robert Easton
Chairman, Scisive Consulting LP
For over 30 years, Bob Easton has been recognized as a world-wide leader in healthcare business consulting. He has built and led two top firms, beginning with the founding of The Wilkerson Group in 1985. He has led scores of market development and strategic advisory assignments for clients, including large and specialty pharmaceutical companies, early-stage through publicly-traded biopharmaceutical companies, and diagnostics businesses. He has influenced the decision-making of numerous healthcare professionals and supported hundreds of client executives in Australia, Japan, Canada, U.S., Europe, and Israel. Mr. Easton's interest in healthcare began when he managed a medical diagnostics business for Union Carbide. Since then he has been highly visible in the industry, having written and spoken about multiple industry issues in scores of venues. He has served on eight medical company Boards including CollaGenex and Cepheid. He also serves as Chairman of Gilda's Club of New York City, which provides social and emotional support to people living with cancer. He is a director of the Global Cardiovascular Innovation Center at Cleveland Clinic, and also of the New York Biotechnology Association [NYBA]. Mr. Easton holds two degrees in Chemical Engineering from Rice University and an MBA from the Harvard Business School.
[ Back to top ]
Bill Facteau
Worldwide President, Acclarent, Inc., a division of Ethicon, Inc.
Bill Facteau joined Johnson and Johnson in January 2010 after Ethicon acquired Acclarent for $785 million in cash. He
currently serves as the worldwide president of Acclarent, a dedicated stand-alone ENT division of Ethicon. Prior to the
acquisition, Bill joined Acclarent and its founders in 2004 as the president, CEO, and a member of the board of directors.
Under his leadership, the company went from concept to acquisition in 5 ½ years, raised over $100 million, created jobs
for approximately 400 employees, grew revenues to $100 million, and became profitable. Prior to joining Acclarent, Bill
was the general manager of the Endovascular Division at Abbott Vascular, where he served as a member of the
executive team and created the entry strategy for Abbott to participate in the peripheral vascular space. He joined
Abbott Laboratories via the $683 million acquisition of Perclose, a vessel-closure company, where he was the area sales director. From July
1993 to April 1998, Bill worked in a number of sales and sales management positions at the United States Surgical Corporation. He received his
B.A. in political science from the University of Connecticut, and is a named inventor on five issued patents.
[ Back to top ]
Richard Ferrari
Managing Director, DeNovo Ventures
Mr. Ferrari is a Co-Founder of De Novo Ventures which has $650 million under management and which is one of the premier firms dedicated to Medical Devices and Bio-Technology.
Additionally, Rich has been a successful CEO of two publicly traded medical technology companies. Cardiovascular Imaging Systems, the first and leading developer of ultrasound imaging catheters which was eventually acquired for $125 million by Boston Scientific. His most recent success, CardioThoracic Systems (CTS), the market leader in disposable instruments and systems for performing minimally invasive beating heart bypass surgery, was acquired by Guidant for $350 million in November 1999. Rich was a co-founder of CTS and the force that led the company to an initial public offering in only 7 months, the fastest of any medical technology company in history. Mr. Ferrari also Co-Founded the Medical Technology Group which spun-out Integrated Vascular Systems, acquired by Abbot Vascular and Ensure, acquired by J&J.
Mr. Ferrari also serves as a faculty member of the Stanford Biodesign Emerging Entrepreneurs Forum, as well as a board member for the Stanford | Coulter Foundation for Translational Medicine.
Previously Mr. Ferrari held the positions of Executive Vice President and General Manager of ADAC Laboratories. In 1996 he founded Saratoga Ventures, a venture capital partnership that has provided seed financing to startup medical technology companies.
Mr. Ferrari is the recipient of the Mallinckrodt Award for Excellence in Medicine and has been a finalist for the Entrepreneur of the Year Award. Rich holds a BS degree from Ashland University and an MBA from the University of South Florida.
[ Back to top ]
Peter Fitzgerald
Director, Center for Cardiovascular Technology, Stanford University
Dr. Peter Fitzgerald is the Director of the Center for Cardiovascular Technology and Director of the Cardiovascular Core Analysis Laboratory (CCAL) at Stanford University Medical School. He is an Interventional Cardiologist and has a PhD in Engineering. He is Professor in both the Departments of Medicine and Engineering at Stanford. Presently, Dr. Fitzgerald's laboratory includes 14 postdoctoral fellows and graduate engineering students focusing on state-of-the-art technologies in Cardiovascular Medicine. He has led or participated in over 95 clinical trials, published over 300 manuscripts/chapters, and lectures worldwide. He has trained over 125 post-docs in Engineering and Medicine in the past decade. Peter has been principle/founder of fourteen medical device companies in the San Francisco Bay Area. He has transitioned nine of these start-ups to large medical device companies. He serves on several boards of directors, advised dozens of medical device startups as well as multinational healthcare companies in the design and development of new diagnostic and therapeutic devices in the cardiovascular arena. In 2001, Peter was on the founding team at LVP Capital, a venture firm, focused on medical device and biotechnology start-ups in San Francisco. In 2008, he partnered, with TriVentures, which is an incubator for early state medical technology in Israel and heads the Stanford-China Med Tech innovation program.
[ Back to top ]
Hanson S. Gifford, III
Managing Member, The Foundry, LLC
Since 1998, Mr. Gifford has led The Foundry in all of its activities. These include the invention, identification and development of new technologies, and the formation, financing, and leadership of new companies. Among the companies The Foundry has created are Evalve (acquired by Abbott Labs), Concentric, Emphasys, First to File, Satiety, Xtent (Nasdaq:XTNT), Cierra, Ardian (Acquired by Medtronic), Cabochon, Miramar, and ForSight Labs, an ophthalmic device incubator. Prior to The Foundry, Mr. Gifford was VP of R&D at Heartport, Inc. From 1993-1998, he led a 62-person team developing novel devices and procedures for minimally invasive cardiac surgery. Heartport had a successful IPO in 1996. In 1992, Mr. Gifford co-founded and served as managing director of Bavaria Medizin Technologie, GmbH, a German developer of catheters for Interventional Cardiology. In 1991, Mr. Gifford served as president of Cardiovascular Therapeutic Technologies, Inc. which was acquired by Eli Lilly. From 1985-1990, Mr. Gifford worked at Devices for Vascular Intervention (DVI) in various Engineering, Clinical Research and Marketing capacities. Before joining DVI, Hanson worked in engineering roles at Oximetrix and General Dynamics. Mr. Gifford is a co-inventor on over 130 issued and 230 published pending US patents. He earned his B.S. degree in mechanical engineering from Cornell University. Mr. Gifford is a Director of Cabochon, Concentric Medical, Miramar Labs, Nexis Vision, and the latest Foundry and ForSight start-ups.
[ Back to top ]
David L. Gollaher
President & CEO, California Healthcare Institute (CHI)
David L. Gollaher, Ph.D., co-founded CHI in 1993. Previously, he was a senior executive at Scripps Clinic and Research Foundation. Earlier in his career, he served on the faculties of Harvard University, University of California, San Diego, the Graduate School of Public Health at SDSU, and the Overseas School of Rome. He is an award-winning historian of science and medicine, and has written three books and numerous articles in the fields of health policy, the economics of biomedical research and development, bioethics and the history of medicine. Gollaher completed his undergraduate studies at the University of California and earned his master's and doctorate degrees from Harvard University. Subsequently, he was a Fellow of Harvard's Houghton Library, the National Endowment for the Humanities, and the Massachusetts Historical Society. Presently, he serves on the boards of CHI, the J. David Gladstone Institutes and sits on the California Council on Science and Technology (CCST) and the Biotechnology Advisory Committee of the California Commission for Economic Development (CED). Gollaher is also a co-founder and board member of Vision Robotics Corp., and holds five patents for vision-based autonomous robotic navigation software.
[ Back to top ]
William A. Hawkins
Retired Chairman and Chief Executive Officer, Medtronic, Inc.
Bill Hawkins assumed the role of Chief Executive Officer of Medtronic, Inc. in August 2007 and became Chairman of the Board in August 2008. Hawkins was named President and Chief Operating Officer in May 2004 after joining Medtronic as Senior Vice President and President of Medtronic's Vascular business in January 2002.
Hawkins joined Medtronic from Novoste Corp., where he had been President and Chief Executive Officer since 1998. Earlier positions included Corporate Vice President and President of the Sherwood Davis and Geck organization of American Home Products; President of the Ethicon Endo-Surgery organization of Johnson & Johnson; President, Devices for Vascular Intervention and President U.S. Operations, for Guidant Corp.; and several increasingly responsible executive positions culminating in the presidency of the IVAC organization for Eli Lilly & Co. He began his medical technology career with Carolina Medical Electronics in 1977.
Hawkins received his Bachelor of Science degree in electrical and biomedical engineering from Duke University in 1976 where he also conducted medical research in pathology. He received a Master of Business Administration Degree from the Darden School of Business, University of Virginia, in 1982.
Hawkins is a member of the Board of Visitors of the Engineering School of Duke University and the Minneapolis Institute of Arts.
[ Back to top ]
Joe Heanue
President, Triple Ring
Joe Heanue is the president and co-founder of Triple Ring Technologies, a firm that provides R&D services and advanced technology to the MedTech, Homeland Security and Defense, and CleanTech industries. Joe has significant leadership experience in device and instrumentation research & development within interdisciplinary environments. He has served as Vice President of Engineering at NexRay and Signature BioScience. At NexRay, Joe led the development of a low-dose x-ray imaging system for interventional cardiology. At Signature, he headed a group that delivered prototype RF and microwave spectroscopy instruments to a major instrument partner; the first of these instruments was launched in 2005 by MDS Sciex. Joe holds a number of patents for medical devices and instruments, including a patent for a medical system imaging architecture that is licensed to a major medical equipment manufacturer. He received a BS in Physics from the Massachusetts Institute of Technology and earned his Ph.D. in Electrical Engineering and Computer Science from the University of California at Berkeley. Joe was a postdoctoral researcher at Xerox PARC, and he has completed the Stanford University Executive Program for Growing Companies.
[ Back to top ]
James M. Heslin
Partner, Wilson Sonsini Goodrich & Rosati
For more than 20 years, James Heslin has focused on helping medical device companies protect and enforce their domestic and international intellectual property rights, as well as advising venture capitalists who invest in medical technology companies. In addition, Jim has extensive experience in investor due diligence, portfolio evaluation, licensing matters, and the preparation of patent validity and infringement opinions. He also counsels clients regarding in-house intellectual property protection programs. James received his J.D. from the UC Berkeley School of Law and his undergraduate degree from the University of California, Santa Barbara, graduating with highest honors. He is admitted to practice in California.
[ Back to top ]
David M. Hoffmeister
Partner, Wilson Sonsini Goodrich & Rosati
David Hoffmeister is a partner at Wilson Sonsini Goodrich & Rosati, where he plays a major leadership role in the drug and device regulatory and healthcare law practice within the firm’s life sciences practice. David has more than 20 years of experience representing pharmaceutical, biotechnology, medical device, diagnostic, and dietary supplement clients. He advises them on a variety of regulatory and healthcare issues, such as strategies for obtaining FDA product approvals and clearances, recalls, labeling, and claim support for advertising and promotional materials. Before joining Wilson Sonsini Goodrich & Rosati, David was senior counsel for drug and device law at Syntex U.S.A., Inc., where he focused primarily upon advising senior management on worldwide issues affecting the ability of the corporation and its affiliates to develop, manufacture, and distribute pharmaceutical, device, diagnostic, and over-the-counter drugs in compliance with the Federal Food, Drug, and Cosmetics Act, as well as implementing regulations and applicable state and federal healthcare laws. David received his J.D. degree from San Francisco Law School and his B.S. degree from the University of the Pacific. He is admitted to practice in California and before various federal courts, including the United States Supreme Court.
[ Back to top ]
Mir Imran
Chairman & CEO, Modulus; Managing Director, InCube Ventures
Mir Imran founded InCube Labs, a multi-disciplinary research lab, and InCube Ventures, a life sciences venture fund, to focus on his passion: creating medical solutions that change the standard of care in critical healthcare markets. Mir began his career as a med-tech entrepreneur in the late 1970's and has founded numerous game-changing companies since those early days. Over the decades, he has become one of the leading inventors and entrepreneurs in healthcare. Mir now holds more than 200 issued patents and is perhaps most well-known for his pioneering contributions to the first FDA-approved Automatic Implantable Cardioverter Defibrillator, a device sold to Eli Lilly and is now part of Guidant. Additionally, Mir has invented a number of breakthrough devices that set new standards of care for their industries. As an entrepreneur, Mir has founded more than 20 medical device companies; 15 of his companies have seen "liquidity events" (IPO/Acquisition). Mir currently holds board seats with Bodymedia, Corhythm, eGeen, Entrack, Fe3, Intrapace, Modulus, Neurolink, NFocus, and Spinal Modulation. Mir is also Chairman and CEO of InCube Labs and Modulus Inc., a manufacturing and product development company focused on the medical device market. For more information on Mir and his companies, go to www.incubelabs.com and www.modulusinc.com.
[ Back to top ]
Eitan Konstantino, Ph.D.
President & CEO, TriReme Medical Inc.
President & CEO, Co-Founder of TriReme Medical, a company that develop, manufacture and distribute differentiated stents and Angioplasty catheters. Trireme has offices in the San Francisco Bay Area and Singapore. Prior to co-founding TMI, Dr. Konstantino was co-founder, president and chief scientist of AngioScore Inc from its inception until 2006. Dr. Konstantino is the primary inventor of the AngioSculpt catheter and the Easy Exchange delivery system. Previously, Dr. Konstantino was the CEO & COO of Advanced Stent Technologies (AST), a bifurcation stent company that was acquired by Boston Scientific in 2004. He co-invented the Petal bifurcation stent that is currently in development at Boston Scientific. Prior to AST, he was Chief Technical Officer of Bypass Ltd, a developer of nitinol anastomotic devices for minimally invasive heart surgery. Dr. Konstantino received his PhD from Technion, Israel's premier engineering school. He currently serves as the co-chairman of the ASTM F04.30.06 Cardiovascular Standards Task Group.
[ Back to top ]
Mattias Kyhlstedt
CEO, Synergus
Mattias Kyhlstedt is the chief executive officer and founder of Synergus AB and Synergus Corp. He has 15 years of experience in reimbursement and Quality & Regulatory in the medical device industry. Mattias has unique management knowledge and insights within medical device companies based on previous positions within business development, production, quality, logistics and R&D in global corporations as well as start-ups. He has considerable experience in development of Pan-European reimbursement and regulatory strategies for medical device companies. Mattias is a frequent speaker at various international conferences in the area of reimbursement, quality and regulatory.
[ Back to top ]
Landon G. Lack
CEO, China MedConnect
Mr. Lack is the CEO of China MedConnect (CMC), a privately held Beijing-based company that exclusively represents US and European medical device companies with their operations in China. CMC is authorized by the China SFDA to conduct medical device registrations, and to act as after-sales service agent and legal representative for US and other Western medical device companies operating in China. CMC enables small and medium size medical device companies to achieve best practices for the Chinese market, something typically only achievable by the largest medical device companies. Prior to CMC, Mr. Lack has worked for both large public companies as well as early stage venture backed companies including; McGaw Inc., now part of B.Braun, Boston Scientific, Ask Jeeves, SealedMedia (ab Oracle), and Capitis Healthcare China. Mr. Lack received his Bachelors of Science degree from the United States Military Academy, West Point, New York, and his MBA from the China Europe International Business School (CEIBS). He has lived full time in China for the past five years and is currently in Beijing with his wife and three daughters.
[ Back to top ]
Mark Leahey
President & CEO, MDMA
Mark Leahey is the president and CEO for the Medical Device Manufacturers Association (MDMA), a national trade association in Washington, D.C., that represents research-driven medical technology companies. Mark’s responsibilities include advocating on behalf of the entrepreneurial sector of the medical device industry to Congress, the Food and Drug Administration (FDA), the Centers for Medicare and Medicaid Services (CMS), and other federal and state agencies. He has lobbied for a more reasonable user fee for smaller companies, worked to open access to the hospital marketplace by challenging the exclusionary and anti-competitive nature of certain large group purchasing organizations (GPOs), as well as to ensure that medical device technologies are reimbursed adequately. Mark currently sits on the Medical Devices Committee for the Food and Drug Law Institute (FDLI) and the Editorial Advisory Board of Medical Product Outsourcing. He is a member of the Massachusetts bar and a graduate of Georgetown University, the Georgetown Law Center, and Georgetown’s McDonough School of Business.
[ Back to top ]
Michael Liang, Ph.D.
Partner, Baird Venture Partners
Mike is a Partner with Baird Venture Partners in Chicago and oversees the group’s healthcare and life science investments, focusing on the areas of medical devices, life science tools, diagnostics, and healthcare services. Prior to joining Baird Venture Partners in 2006, he worked with Advent Venture Partners, a life sciences tech and VC firm based in London, UK. Prior to Advent, he served as a Director of R&D at Cortek, Inc., a medical devices company in Dedham, Mass, where he was responsible for the development of three spinal orthopedic products. Mike is currently a member of the board of directors of Palyon Corporation, PathCentral, Inc., and Veniti, Inc. Previously, he was a board member of Interlace Medical before its acquisition by Hologic in 2011. Mike is also a member of the Rush University Medical Center Associates Board and is a Catalyst for the Wisconsin Alumni Research Foundation (WARF) Accelerator Program. Mike received a B.S. from the University of California Berkeley and a Ph.D. in biophysical chemistry from Stanford University. He also conducted a postdoctoral fellowship at Harvard University.
[ Back to top ]
Jack Lloyd
Founder, Nellcor and Alere Medical
Jack Lloyd has founded and managed several high tech companies in the medical device, medical service, and drug delivery sectors. Since 2006, he served as founder and principal in several companies developing drug delivery systems and non-invasive measurement and monitoring. Jack also serves as director of Alere Medical, which specializes in monitoring patients at home for heart failure and other chronic diseases. From 1993 to 2000, he was founder, president, and chairman of Aradigm, a company that developed, manufactured, and licensed devices and systems for aerosol drug delivery for systemic effect, including insulin. He led the company through its initial public offering in 1996.
Prior to his work with Aradigm, he was founder and president of anesthesia monitoring company Nellcor Incorporated, which developed of the pulse oximeter and launched its initial public offering in 1987. Jack has served on the public boards of Nellcor, Aradigm, Aspect Medical, and Molecular Dynamics, and he is a director, investor, and advisor to several medical device and drug delivery companies. He also serves on the advisory committee to the dean of the College of Engineering at the University of California, Berkeley, and as chairman of the Bioengineering Industrial Advisory Board at Berkeley. He has a BSME from University of California, Berkeley and holds 30 U.S. Patents.
[ Back to top ]
Joshua Makower
CEO & Founder, ExploraMed Development, LLC
Josh has dedicated his life to the creation of medical technologies which improve the quality of life for patients and is the CEO and Founder of ExploraMed Development, LLC, a medical device incubator based on the west coast. He is also a Venture Partner with New Enterprise Associates where he supports the investing activity in the medical device arena. Josh serves as a Consulting Associate Professor of Medicine at Stanford University Medical School and co-founded Stanford’s Biodesign Innovation Program. A compendium of the materials created to support the teaching efforts in the Stanford Biodesign program has recently been published under the Cambridge University text title of: Biodesign: The Process of Innovating New Medical Technologies. Josh has founded several companies through the ExploraMed incubator which have achieved successful M&A transactions including Acclarent, Inc., a company focused on developing novel therapies in ENT, which was acquired by J&J in 2010, TransVascular, Inc., a company focused on the development of a completely catheter-based coronary bypass technology, which was acquired by Medtronic, Inc. in 2003, and EndoMatrix, Inc., a company focused on the development of a novel therapy for incontinence and GI Reflux, which was acquired by C.R. Bard in 1997. Up until 1995, Josh was Founder and Manager of Pfizer’s Strategic Innovation Group, a group chartered to create new medical device technologies and businesses for Pfizer’s medical device businesses. Josh also serves on the Board of Directors for NeoTract, Inc., Moximed, Inc., Intrinsic Therapeutics, Inc., ExploraMed III, Inc. and Vibrynt, Inc. Josh holds over five dozen patents for various medical devices in the fields of Orthopedics, ENT, Cardiology, General Surgery, Drug Delivery and Urology. Josh holds an M.B.A. Columbia University, an M.D. from the New York University School of Medicine, and an S.B. in Mechanical Engineering from the Massachusetts Institute of Technology.
[ Back to top ]
Allen May
Founder, Life Science Angels; Managing Partner, Emergent Medical Partners
Allan is a founder of Life Science Angels (www.lifescienceangels.com), the largest angel organization in the U.S. focused solely on early stage medical device and life science start-ups, and comprised solely of high net worth individuals from the medical device or biotech fields. Since 2005, LSA has invested $30M in 30 early stage companies, attracted in excess of $600M in contemporary or follow-on venture capital, and achieved four favorable exits.
In 2007, Allan joined renowned inventor, entrepreneur and cardiac surgeon, Dr. Thomas Fogarty, in co-founding Emergent Medical Partners, solely focused on early stage medical device company creation and investing. EMP has made 22 investments to date.
In 2010, Allan was elected Chairman of the Board of the Kauffman Foundation's Angel Capital Education Foundation, now known as the Angel Resource Institute. ARI, a nonprofit devoted to the promotion and study of angel investing, works closely with the Angel Capital Association in furthering angel investing and entrepreneurial mentoring. In 2011, ARI and ACA were invited to join the White House Start UP America Initiative.
Allan has founded or invested in over 50 medtech and biotech startups, and lectures frequently on trends and developments affecting early stage biotech and medtech investing. He participated in the Singularity University FutureMed Program, spearheading the Innovation and Entrepreneurship session, and is a member of the editorial board of Elsevier Windhover's In Vivo magazine.
[ Back to top ]
John McDonough
CEO & President, T2 Biosystems, Inc.
John McDonough joined T2 Biosystems in 2007. Prior to joining T2, John was president of Cytyc Development Corporation and had responsibility for designing and executing Cytyc Corporation's acquisition and investment strategy for growing the company from a single product company with revenue of approximately $300 million in 2003 to a company with revenue of approximately $750 million from multiple products in 2007. In total, Cytyc acquired five companies totaling over $1 billion in acquisitions and also entered into alliances and investments with several early stage companies. John led the efforts that resulted in Cytyc's acquisition by Hologic, Inc. in October, 2007 for over $6 billion, representing a four times increase in Cytyc's market cap over a four year period. During John's tenure at Cytyc, he also had responsibility for Cytyc's Research & Development, Operations and Regulatory functions. John came to Cytyc after serving as co-founder, CEO and president at SoundBite Communications, a customer communications company which went public in 2007. Previously, he was COO of Direct Hit Technologies, an Internet search engine company that was successfully acquired in January, 2000 for over $500 million, and CEO and President of Workgroup Technology, a publicly held company that developed and marketed product development management solutions. John also spent 10 years with Easel Corporation where he held the role of CFO, COO and then CEO of a start-up company that grew into a publicly held company in 1990 and which was acquired in 1995. John was a member of the Board of Directors for Interlace Medical, a developer of medical devices for treating gynecological diseases which was acquired by Hologic, Inc. in January, 2011. John was also a member of the Board of Directors of CRi, a developer of optical imaging systems for biomedical research and molecular-based drug and diagnostic development. CRi was acquired by Caliper Life Sciences in December, 2010. John graduated Magna Cum Laude from Stonehill College in 1981.
[ Back to top ]
Casey McGlynn
Partner, Wilson Sonsini Goodrich & Rosati
Casey McGlynn is a partner at the law firm of Wilson Sonsini Goodrich & Rosati. He serves as a member of the board of directors and, since joining the firm in 1978, has been a member of the firm's Policy, Nominating, and Compensation Committees. Casey’s practice focuses on the organization, funding, and corporate representation of companies in the information technology, life sciences, and telecommunications industries. He is a nationally recognized leader in the representation of start-up and growth technology companies. Casey assists his clients in meeting their financing needs through introductions to an extensive network of angel investors, financiers, venture capitalists, corporate partners, and investment bankers. He has experience representing dozens of companies that have made successful initial public offerings and secondary offerings. He frequently is called upon to structure and negotiate mergers and acquisitions, licensing arrangements, and domestic and international strategic corporate alliances, as well as other innovative financing arrangements. Casey is a frequent speaker and written contributor on issues relating to the organization and funding of new ventures. He was recognized in the 2005-2010 editions of Chambers USA: America's Leading Lawyers for Business for "his life sciences, information technology, and telecom expertise." Casey received his J.D. and B.A. degrees, with highest honors, from Santa Clara University. He is admitted to practice in California.
[ Back to top ]
Erin McGurk
President & CEO, PneumRx, Inc.
Ms. Erin McGurk is currently a founder and the president and chief executive officer of PneumRx, Inc. PneumRx is a start-up medical device company in the pulmonary market. She is also a founder and serves on the Board of Directors for Tenaxis Medical. Previously, Ms. McGurk was a founder and Managing Director of Magic Venture Capital, LLC (MVC). MVC was a seed investor in such successful companies as Atrionix (acquired by Johnson & Johnson) and Spinal Concepts (acquired by Abbott Labs), of which Ms. McGurk was a founder. She served on the Board of Directors for both companies and was Chairman of the Board for Vector Medical. Ms. McGurk was a founder, executive board member and Vice President of Technology for Micro Interventional Systems (acquired by Medtronic). Prior to MIS, Ms. McGurk held executive positions at Baxter Healthcare, Cordis, Dow Corning Wright and American Medical Electronics. She is an inventor on numerous issued patents and patent publications. Ms. McGurk holds a B.S. degree in biological sciences from California State University, Long Beach and an M.S. degree in mechanical engineering (bioengineering) from University of California, San Diego.
[ Back to top ]
King Nelson
President & CEO, Uptake Medical
R. King Nelson joined Uptake Medical on April 9, 2007. His experience spans over 25 years in the healthcare and life-sciences industry with firms such as American Hospital Supply Corporation, Baxter International, VenPro Corporation and Kerberos Proximal Solutions. Mr. Nelson was president and CEO of Kerberos from 2006-2007. Kerberos, a privately held medical device firm was acquired by FoxHollow Technologies in September 2006. Mr. Nelson was CEO and president of VenPro Corporation from 1999-2004. VenPro, a privately held medical device firm, focused on replacement of heart valves and venous valves. The company’s pulmonary heart valve business was purchased by Medtronic in 2002. The company was acquired by 3F Therapeutics in 2004. From 1980-1999 Mr. Nelson was with American Hospital Supply Corporation and Baxter International. He held several division president and general manager positions including President of Baxter Perfusion Services form 1996-1999, President Bentley Division 1993-1996 and President of Dade Diagnostics 1990-1993. From 1980-1990 he held several sales and marketing positions in the companies. Mr. Nelson graduated from Texas Tech University with a Bachelors Degree and MBA from the University of Miami. He is involved with numerous charity and civic groups. He is presently on the Board of Directors of Digirad Corporation, a medical imaging and service company. He also serves on The President’s Council for the University of Miami and the Board of Director’s for the College of Mass Communications at Texas Tech University.
[ Back to top ]
Mika Nishimura
VP, Commercial Development, Auxogyn, Inc.
Mika Nishimura is a seasoned senior executive with over 20 years of leadership experience in medical device industry. During her tenure as the Director of Global Marketing at Guidant Vascular Intervention and Vice President, International Sales Operations and Marketing at ev3, Inc., Ms. Nishimura started and built franchises contributing significant, consistent revenue and profit growth with operations in over 30 markets. In 1999, Ms. Nishimura founded The BLG Group, a leading consulting practice advising both investors and device companies. Her clients have sought her group’s advice on critical strategic initiatives ranging from identifying high-priority acquisition targets, developing a product/technology road map based on rigorous analyses and strategic thinking, or creating and executing a geographical expansion plan. She is a frequent speaker at medical device and life science conferences.
In April 2011, Ms. Nishimura became Vice President, Commercial Development for Auxogyn, Inc., an early-stage life science company focused on improving success rates of in-vitro fertilization procedures. Additionally, Ms. Nishimura is an Operational Partner of Gilde Healthcare, a life sciences venture capital firm based in the Netherlands. Ms. Nishimura holds an MBA from the Harvard Business School and a BA in Economics with distinction, summa cum laude from Yale University.
[ Back to top ]
Philip H. Oettinger
Partner, Wilson Sonsini Goodrich & Rosati
Philip Oettinger is a partner in the life sciences practice at Wilson Sonsini Goodrich & Rosati, where he focuses primarily on medical device, biotechnology, and pharmaceutical companies. Philip’s practice involves assisting private and public companies with corporate governance, initial public offerings, mergers and acquisitions, and private equity financings. From 1995 until 2000, he was with the Securities and Exchange Commission in Washington, D.C., where he inspected stock exchanges, worked on corporate finance and stock market structure issues, and led enforcement investigations. His select list of clients includes De Novo Ventures, FoxHollow Technologies, InterWest Partners, Perlegen Sciences, Ventana Medical Systems, Vertical Group, and XTENT. Philip received his J.D. degree from the Washington College of Law and his B.S. degree from Cornell University. He is admitted to practice in California, Massachusetts, New York, and the District of Columbia.
[ Back to top ]
Hank Plain
Partner, Morgenthaler Ventures
Hank Plain joined Morgenthaler Ventures as a Partner in 2007 after 25 years in the life science industry, including co-founding eight medical device start-ups and directing the exits of six companies with a combined value in excess of $3 billion. He is based in Menlo Park, California and is focused on medical device investments. In January 2011 Medtronic acquired Ardian for $800 million, plus uncapped annual revenue growth milestones that are projected by Wall Street analysts to return an additional $550M to Ardian’s investors. Hank was a founder, helped incubate Ardian at The Foundry and served as a director of the company. Since 2005, Hank was an independent board member and served on the deal committee that helped to successfully negotiate the January 2010 acquisition of Acclarent by Johnson & Johnson for $785 million.
Hank is Vice Chairman of The Foundry, where he co-founded Ardian, Cabochon, ForSight Labs, ForSight Vision2, Miramar, Satiety and Transcend. He is a board member at Access Closure. From 1993-2000 he served as President and CEO of Perclose, when he led the company to $100 million in sales, a successful IPO in 1995 and acquisition in 1999 by Abbott Labs. He was Chairman of Embolic Protection, where he helped negotiate the acquisition in 2001 by Boston Scientific. He also served as a Director at TransVascular until the Medtronic acquisition in 2003.
[ Back to top ]
Ferolyn Powell
Divisional VP & General Manager, Structural Heart, Abbott Vascular
Ferolyn Powell is an executive with more than 25 years experience in the medical device industry. She is currently Divisional Vice President and General Manager, Structural Heart, Abbott Vascular. Previously, she was President, CEO and Director of Evalve, Inc. Prior to joining Evalve in 1999, Ms. Powell held various positions at General Surgical Innovations (acquired by Tyco) including Vice President of Operations, with responsibility for Quality and Regulatory Affairs. Ms. Powell also previously served as head of R&D at Adjacent Surgical (acquired by GSI), and Director of R&D at Devices for Vascular Interventions (DVI), Guidant Corporation’s atherectomy catheter division. Prior to DVI, Ms. Powell held various technical management positions at Frantz Medical Development and Life Systems, Inc. She holds an M.S.E. degree in Biomedical Engineering from the University of Akron and a B.S. degree in Chemical Engineering from Cleveland State University.
[ Back to top ]
Sushma Selvarajan
Head of Business Development & Strategy, Roche Molecular Diagnostics
Sushma Selvarajan, Head of Business Development & Strategy for Roche Molecular Diagnostics (RMD), joined RMD in October 2010, bringing a background in pharmaceutical chemistry, cell biology and developmental biology. She is responsible for RMD's external partnerships from initial strategy through deal completion, including R&D collaborations, in- and out-licensing, and Companion Diagnostics partnerships with pharmaceutical companies. She came to RMD from Roche Diagnostics in Basel, Switzerland, where she was Global Business Development Manager since March 2007. From October 2003 to February 2007, Sushma was with Roche Palo Alto, first as Senior Portfolio Strategy Analyst and then Portfolio Strategy Manager. Prior to Roche, Sushma held various positions in operations and product development at Ingenuity Systems in Mountain View, CA.b Sushma holds a PhD in Pharmaceutical Chemistry from University of California, San Francisco, CA, and an AB in Biochemistry from Mount Holyoke College in South Hadley, MA. She is fluent in English, German, Italian and Hindi.
[ Back to top ]
Elton Satusky
Partner, Wilson Sonsini Goodrich & Rosati
Elton Satusky is a partner at Wilson Sonsini Goodrich & Rosati, specializing in public and private securities offerings, mergers and acquisitions, and corporate governance. A large number of his clients are public and private venture-backed life science and medical technology companies. From 1998 to 2000, Elton worked at Davies Ward Phillips & Vineberg in Toronto, Canada, where his practice primarily focused on public offerings and mergers and acquisitions for large multinational companies. He received his LL.B. degree from the Osgoode Hall Law School and completed two years towards a B.S. at York University. He is admitted to practice in California and Ontario, Canada.
[ Back to top ]
Greg B. Scott
President & Founder, ChinaBio® LLC President & Co-founder, Life Science Angels
Greg is an entrepreneur, angel investor and business advisor who has helped launch over thirty life science companies in the U.S. and China. He founded ChinaBio® LLC in January 2007 to identify and develop early stage life science companies in China. Since then, ChinaBio has now grown into a 15 person consulting, market research and advisory firm helping US and European companies identify potential partners and novel technologies in China, and China-based companies raise VC and government funding. ChinaBio has also organized ten investment conferences and three partnering conferences in China. Greg is also the president and co-founder of Life Science Angels, an angel investment group that has funded 38 biotechnology and medical device companies since 2005, and Executive Editor of the ChinaBio® Today newsletter. Greg lives and works in Shanghai but visits the US several times a year to enjoy California’s blue sky and sandy beaches.
[ Back to top ]
Mark S. Speers
Partner and Managing Director, Health Advances, LLC
Mark co-founded Health Advances in 1992 after gaining ten years of strategy consulting experience in the healthcare industry as a Partner at Bain & Company, an international management consulting firm. Most of his client projects over the last 19 years at Health Advances have focused on evaluating the commercial potential and/or developing market launch strategies for new medical devices and diagnostics. In addition, he has been deeply involved in numerous mergers and acquisitions totaling over $35 billion in transaction value. Mark earned his Engineering undergraduate degree at Dartmouth College, Magna Cum Laude and Phi Beta Kappa. He received his MBA from the Stanford Graduate School of Business where he was honored as an Arjay Miller Scholar. Mark serves on the Advisory Boards of Water Street Healthcare Partners, Safeguard Scientifics, and Radius Ventures. Mark recently completed a 6-year term as an active participant of the Board of Directors for MassMEDIC.
[ Back to top ]
William Starling
Managing Director, Synergy Life Science Partners and CEO, Synecor
William Starling is managing director of Synergy Life Science Partners (www.synergylsp.com) and CEO of Synecor, a business generator of new Life Science companies based in Research Triangle Park, North Carolina, Santa Rosa, and Portola Valley, California. Synecor (www.synecor.com) has significant academic, scientific, physician, venture capital, and corporate partnerships and is focusing its efforts on the identification and development of proprietary, disruptive technologies with extraordinary market potential in the life sciences field. William Starling received his BSBA degree from the University of North Carolina at Chapel Hill and his MBA degree from the University of Southern California. He began his 33 year career in the medical technology device industry at American Edwards Laboratories. He was subsequently part of the founding management team and Director of Marketing for Advanced Cardiovascular Systems, Inc. (acquired by Lilly in 1984), and was a cofounder, Vice President and Board member of Ventritex, Inc. (IPO in 1992, acquired by St. Jude Medical in 1997). He was a cofounder and Chairman of the Board of Directors and CEO of Cardiac Pathways Corporation (IPO in 1996, acquired by Boston Scientific Corporation in 2001). In addition, Mr. Starling was co-founder and initial CEO of Synecor spinout Bioresorbable Vascular Scaffold (BVS) prior to its acquisition by Guidant in 2003. Mr. Starling serves as Chairman of the Board of Visitors at the Kenan-Flagler Business School at UNC.
[ Back to top ]
Robert Stockman
Chairman & CEO, Reva Medical
Bob Stockman is the Chief Executive Officer of REVA Medical, Inc., which he helped to co-found in 1999. He has been involved in five other med-tech startups and buyouts in the past 25 years as a founding principle and executive. He has degrees from Harvard College and the Amos Tuck School of Business at Dartmouth.
[ Back to top ]
John Sullivan
Principal, Foundation Medical Partners
Mr. Sullivan has over twelve years of operating experience in the health care industry, with a focus on medical devices and biotechnology. Before joining Foundation, he helped start Molecular Staging Inc., a biotechnology company spun out of the Yale School of Medicine that he joined as the first full-time employee. He served as Director of Business Development until the successful sale of the company to Qiagen, GmbH. Following this, he served as a consulting entrepreneur for a variety of early stage healthcare technology companies, with a particular emphasis on business strategy and product development. Prior to his entrepreneurial experiences, Mr. Sullivan led the development of the first coronary stent at Boston Scientific Corporation. He began his career developing marketing strategies for Johnson & Johnson while working for Saatchi & Saatchi Advertising. Mr. Sullivan holds a B.S. in Industrial Engineering degree with distinction from Stanford University and an M.B.A. from the Stanford University Graduate School of Business.
[ Back to top ]
Irene Tanner
Managing Director, China eCapital
Ms. Tanner is a Managing Director of China eCapital, a leading privately held investment bank in China, that provide advisory services in Mergers & Acquisitions (M&A), Joint Ventures, Private Placements, and Initial Public Offerings (IPO). China eCapital specializes in cross-border transactions and has strong vertical expertise in i ) health care and life sciences, ii ) technology, media and entertainment, iii ) consumer products and services, and iv ) cleantech. Ms. Tanner has been with China eCapital since its inception in 2000, during which time she has worked with Chinese and multinational clients in the medical device, diagnostics, healthcare services, CMO, and pharmaceutical sectors.
Ms. Tanner began her career as an engineer for Merck and worked on several plant start-ups, including a technology transfer project for a Recombinant Hepatitis B vaccine in Beijing and Shenzhen. She also helped start-up Merck’s joint venture facility in Hangzhou. During her time with Merck, she also worked on the launch of Crixivan (protease inhibitor for AIDS ) and a pediatric formulation of Singulair (asthma). She also travelled throughout Merck international manufacturing facilities to inspect, evaluate, and rationalize new capital upgrades. After Merck and prior to joining China eCapital, Ms. Tanner worked for Accenture’s (formerly Andersen Consulting) Strategic Services practice in San Francisco, working within their Healthcare and Electronics & High-Tech business practices. She developed market entry strategies for manufacturers and retailers, which included analysis of the market structure and potential acquisition strategies. She has experience in strategy formulation, competitive and market analyses, and financial forecasting. Ms. Tanner has both her MBA and BS in Mechanical Engineering from UC Berkeley.
[ Back to top ]
Martin (Marty) Waters
Partner, Wilson Sonsini Goodrich & Rosati
Martin (Marty) Waters is a corporate and securities partner in our San Diego office. He is a founding partner of the Firm’s San Diego office and Southern California Corporate Practice and a member of the Firm’s Policy Committee. He was a partner in our Palo Alto office until opening the San Diego office in 2004. Marty is a proven company builder with nearly 20 years of experience counseling emerging growth medical device, diagnostics and healthcare IT companies from inception through exit or initial public offering. A partial list of his successful emerging growth clients includes Ablation Frontiers, CoreValve, eyeonics, Helixis, Illumina, N Spine, SenoRx and TearLab. Marty also represents several public companies in a general counsel capacity, as well as investment banks and placement agents in PIPEs and public offerings of equity and debt. Marty has counseled issuers and underwriters in more than 50 offerings while at WSGR and formerly with Cahill Gordon & Reindel and Akin Gump Strauss Hauer & Feld in New York.
[ Back to top ]
Chen Yu, M.D., M.B.A.
Partner, Vivo Ventures
Dr. Yu is an M.D., M.B.A. graduate of Stanford University with extensive operating experience in a broad array of industries with stints at aQuantive, Eli Lilly, and Bain & Co. He is also currently the Chief Business Officer at China KangHui Holdings (NYSE: KH), a leading domestic orthopedic company in China. At Vivo, his interest is in both pharmaceutical and medical device companies and he currently serves on the boards of many life science companies, including Synaptic International (a Chinese based cardiovascular device company), Sagent Pharmaceuticals (NASDAQ:SGNT), KSP, a China/US joint venture between Kang Hong Pharmaceuticals and Sagent Pharmaceuticals, and Nora Therapeutics. He has also been a director at the board of governors of the Stanford University Medical School Alumni Association since 2009. Dr. Yu graduated magna cum laude in biology from Harvard University, his M.D. from Stanford University Medical School and his MBA degree from Stanford University Graduate School of Business.
[ Back to top ]
|
